New study shows that Orca-T, a high-precision donor cell therapy, can be reliably manufactured and delivered at scale. Orca-T is an investigational alternative to traditional bone marrow transplants for blood cancers such as AML, ALL, and MDS. It uses a carefully selected mix of donor immune cells to lower the risk of graft-versus-host disease (GVHD).
In an analysis of 243 patients from Phase 1b and Phase 3 trials, 100% received their planned dose, and 99% of treatments were delivered within the required 72-hour window. Despite different donors, the final products were highly consistent in cell purity and dosage. The therapy includes highly purified regulatory T cells to reduce GVHD, along with controlled doses of stem cells and conventional T cells to restore blood production and fight cancer.
Clinical results from the Precision-T trial showed strong benefits, with 78% of patients alive without chronic GVHD compared with 38.4% for standard transplants, and severe GVHD rates reduced to 12.6% versus 44%. The U.S. Food and Drug Administration has granted Priority Review for Orca-T, supporting its potential for broader clinical use.